Skip to main content
$93.67 -$0.31 (-0.3%)

04:00 PM EDT on 10/25/21

EXACT Sciences Corp (NASDAQ:EXAS)

CAPS Rating: 4 out of 5

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

Current Price $93.67 Mkt Cap $16.2B
Open $93.37 P/E Ratio 0.00
Prev. Close $93.67 Div. (Yield) $0.00 (0.0%)
Daily Range $92.16 - $93.93 Volume 1,669,096
52-Wk Range $89.65 - $159.54 Avg. Daily Vol. 1,289,926

Caps

How do you think NASDAQ:EXAS will perform against the market?

Add Stock to CAPS Watchlist

All Players

312 Outperform
34 Underperform
 

All-Star Players

64 Outperform
8 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:EXAS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

odocoileus (59.09)
Submitted January 31, 2020

They say that there are no atheists in foxholes. You know what I think? I think that all of those Cologuard atheists out there are going to be reborn when it comes time for their first colonoscopy. They'll be singing the praises of Cologuard while… More

zzlangerhans (99.00)
Submitted June 26, 2016

Exact stock does well when something happens to fuel speculation about the long-term profitability of Cologuard, and badly when actual quarterly revenues and losses are released. That reminds me of another stock that has a large cult following and… More

NASDAQ:EXAS VS S&P 500 (SPY)

Fools bullish on NASDAQ:EXAS are also bullish on:

Fools bearish on NASDAQ:EXAS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EXAS.

Recs

0
Member Avatar XMFFlygal (99.49) Submitted: 7/30/2021 5:30:18 PM : Outperform Start Price: $96.20 NASDAQ:EXAS Score: -44.24

Total revenue was $434.8 million, an increase of 62 percent
Screening revenue was $263.9 million, an increase of 101 percent
Screening revenue included a one-time downward adjustment of $12.1 million related to the passing of the contractual deadline to submit claims for previously completed Cologuard tests
Precision Oncology revenue was $137.8 million, an increase of 34 percent
COVID-19 testing revenue was $33.1 million, a decrease of 4 percent
Gross margin including amortization of acquired intangible assets was 69%, and non-GAAP gross margin excluding amortization of acquired intangible assets was 74%
Net loss was $176.9 million, or $1.03 per share, compared to a net loss of $68.1 million, or $0.45 per share
EBITDA was $(122.9) million and adjusted EBITDA was $(26.5) million
Cash, cash equivalents, and marketable securities were $1.31 billion at the end of the quarter

Recs

0
Member Avatar TMFRetireFoolish (< 20) Submitted: 7/8/2021 1:22:52 AM : Outperform Start Price: $122.62 NASDAQ:EXAS Score: -29.83

Potential to build on Cologuard success with multi-cancer screening

Recs

0
Member Avatar Car12703 (49.33) Submitted: 5/12/2021 9:41:10 AM : Outperform Start Price: $97.26 NASDAQ:EXAS Score: -14.22

From Fidelity May 2021:
Revenue Growth (Last 5 Years) = 106.8%
Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 57.8%
Price/Sales (TTM) = 10.0

Leaderboard

Find the members with the highest scoring picks in EXAS.

Score Leader

jpmj

jpmj (73.04) Score: +3,043.64

The Score Leader is the player with the highest score across all their picks in EXAS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
proisback 50.80 9/24/2009 Outperform 3M $2.88 +3,152.43% +328.03% +2,824.40 1 Comment
theonlypro4U < 20 9/23/2009 Outperform 3M $2.89 +3,141.18% +323.38% +2,817.80 1 Comment
chas1232123 < 20 9/23/2009 Outperform 3Y $2.91 +3,119.01% +325.51% +2,793.50 1 Comment
coolyo514 88.79 12/17/2009 Outperform 5Y $2.94 +3,088.11% +312.12% +2,776.00 0 Comment
DUTCHMAN67 63.24 12/17/2009 2/16/2012 Outperform 5Y $2.96 +3,065.60% +312.94% +2,752.66 0 Comment
JavaChipFool 58.29 12/22/2009 Outperform 5Y $2.97 +3,053.77% +307.32% +2,746.44 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. pantastic 81.18 12/17/2009 Outperform 5Y $2.98 +3,043.39% +312.68% +2,730.72 0 Comment
NickJ100 83.46 12/17/2009 9/24/2014 Outperform 1Y $3.01 +3,011.96% +311.82% +2,700.14 0 Comment
JordanKay36 < 20 12/18/2009 Outperform 5Y $3.06 +2,961.11% +313.31% +2,647.80 0 Comment
rdswilson < 20 12/18/2009 Outperform 5Y $3.06 +2,961.11% +313.31% +2,647.80 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EXAS.